Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 3/20 | 0.54 |
| ▸ | CTSS | P25774 | 3/20 | 0.54 |
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.54 |
| ▸ | ITGAV | P06756 | 2/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | ECE1 | P42892 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 3/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2367199 | 0.92 | ITGB3 (0.60) | CTSBCTSSCTSLITGB3ITGAV | |
| SCHEMBL2366818 | 0.92 | ITGB3 (0.60) | CTSBCTSSCTSLITGB3ITGAV | |
| SCHEMBL4088197 | 0.87 | CTSB (0.47) | CTSBCTSSCTSLITGB3ITGAV | |
| SCHEMBL2367935 | 0.86 | KLK5 (0.54) | CTSBCTSSCTSLITGB3ITGAV | |
| SCHEMBL2367312 | 0.86 | KLK5 (0.54) | CTSBCTSSCTSLITGB3ITGAV | |
| SCHEMBL2367698 | 0.84 | CTSS (0.44) | CTSBCTSSCTSLITGB3ITGAV | |
| SCHEMBL9956406 | 0.84 | ACE (0.63) | CTSBCTSSCTSLITGB3ITGAV | |
| SCHEMBL9956403 | 0.84 | ACE (0.63) | CTSBCTSSCTSLITGB3ITGAV | |
| SCHEMBL6763708 | 0.82 | ITGB3 (0.60) | CTSBCTSSCTSLITGB3ITGAV | |
| SCHEMBL5134409 | 0.82 | CTSL (0.72) | CTSBCTSSCTSLITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
| EP-2007794-A1 | LYSOBACTIN AMIDES | AiCuris GmbH & Co. KG (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007118691-A1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | CTSB 236/4885CTSS 660/4885CTSL 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.